Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. (February 2020)

• Record Type: Journal Article
• Authors: Weber, Matthias M.; Gordon, Murray B.; Höybye, Charlotte; Jørgensen, Jens Otto L.; Puras, Gediminas; Popovic-Brkic, Vera; Molitch, Mark E.; Ostrow, Vlady; Holot, Natalia; Pietropoli, Alberto; Biller, Beverly M.K.
• Is Part Of: Growth hormone & IGF research. Volume 50(2020)
• Page Start: 71
• Page End: 82
• Publication Date: 2020-02
• Subjects: Growth hormone deficiency in adults -- Growth hormone replacement -- NordiNet® International Outcome Study (IOS) -- ANSWER Program -- Effectiveness -- Safety -- Body composition -- IGF-I SDS -- Real-world data; Growth regulators -- Periodicals; Growth -- Regulation -- Periodicals; Somatomedin -- Periodicals; Somatomedins -- Periodicals; Growth Hormone -- Periodicals; Growth Substances -- Periodicals; Croissance -- Régulation -- Périodiques; Croissance -- Régulateurs -- Périodiques; Somatotrophine -- Périodiques; Somatomédine -- Périodiques; Growth -- Regulation; Growth regulators; Electronic journals; Periodicals; Electronic journals; 612.4
• DOI: 10.1016/j.ghir.2019.09.002
• Languages: English
• ISSNs: 1096-6374

Abstract

Abstract: Objective : This report describes the effectiveness and safety of growth hormone replacement in 3180 adult patients with growth hormone deficiency followed-up for 0.0–12.2 years in two completed, complementary, non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128 ) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program (NCT01009905 ). Design : In both studies, Norditropin® (somatropin; Novo Nordisk A/S, Denmark) was administered at the discretion of the treating physician and according to routine practice. We present data on baseline characteristics, growth hormone dose, safety data and change from baseline in waist circumference, body mass index and bioimpedance (NordiNet® IOS only). Results : Mean (SD) baseline characteristics (effectiveness analysis set) in NordiNet® IOS ( n = 971) and ANSWER ( n = 304): females, 45%; 69%; mean growth hormone dose (mg/day) (female, 0.338 [0.177]; male, 0.289 [0.157]); (female, 0.501 [0.313]; male, 0.505 [0.351]). Most patients had BMI ≥25 kg/m 2 . Median (P10, P90) exposure (females, 3.5 [0.42, 11.0]; 1.6 [3.2; 0.3, 8.6]; males, 4.1 [0.33, 10.8]; 2.3 [2.9; 0.0, 7.5] years). Mean (SD) change from baseline for waist circumference (−0.46 [6.38] cm [ n = 403], BMI (0.30 [3.30] kg/m 2 [ n = 857]) and bioimpedance (−17.4 (59.19) ohm [ n = 239]) were associated with growth hormone dose (waist/bioimpedance) and duration of follow-up (BMI/bioimpedance). No new safety signals were observed among patients in the full analysis set (NordiNet® IOS, n = 2321; ANSWER, n = 859). Conclusions : Long-term growth hormone replacement is associated with an improvement in body composition. The accumulated data from >10 years of follow-up support the long-term effectiveness and safety of growth hormone replacement as prescribed in clinical practice. Highlights: We report data from 2 large ( n = 3180) non-interventional studies in adults with GHD. Long-term GH (>10 years) was associated with an improvement in body composition. Data support the effectiveness and safety of GH in usual clinical practice.